These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 17223657

  • 1. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
    van Woerkom JM, Kruize AA, Geenen R, van Roon EN, Goldschmeding R, Verstappen SM, van Roon JA, Bijlsma JW.
    Ann Rheum Dis; 2007 Aug; 66(8):1026-32. PubMed ID: 17223657
    [Abstract] [Full Text] [Related]

  • 2. Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sjögren's syndrome.
    van der Heijden EH, Hartgring SA, Kruize AA, Radstake TR, van Roon JA.
    Expert Rev Clin Immunol; 2019 Jul; 15(7):801-808. PubMed ID: 31192747
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression.
    Bikker A, van Woerkom JM, Kruize AA, van der Wurff-Jacobs KM, Bijlsma JW, Lafeber FP, van Roon JA.
    Ann Rheum Dis; 2012 Dec; 71(12):1934-41. PubMed ID: 22563027
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [Abstract] [Full Text] [Related]

  • 5. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
    Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H.
    Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
    [Abstract] [Full Text] [Related]

  • 6. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
    Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
    Ann Rheum Dis; 2008 Nov; 67(11):1541-4. PubMed ID: 18276741
    [Abstract] [Full Text] [Related]

  • 7. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
    Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.
    Arthritis Res Ther; 2006 Nov; 8(4):R129. PubMed ID: 16859536
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lupus erythematosus with leflunomide: induction or reactivation?
    Gensburger D, Kawashima M, Marotte H, Kanitakis J, Miossec P.
    Ann Rheum Dis; 2005 Jan; 64(1):153-5. PubMed ID: 15608317
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q, Wang S, Jiang H, Liu L.
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [Abstract] [Full Text] [Related]

  • 11. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M, Sasaki T, Kaneko Y, Yasuoka H, Suzuki K, Yamaoka K, Takeuchi T.
    Clin Exp Rheumatol; 2018 Mar; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [Abstract] [Full Text] [Related]

  • 12. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study.
    Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F.
    J Rheumatol; 2004 Jan; 31(1):96-101. PubMed ID: 14705226
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X.
    Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
    [Abstract] [Full Text] [Related]

  • 14. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C, Zernicke J, Hagemann A, Gamboa LM, Callhoff J, Burmester GR, Feist E.
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, Wei W, Lin B, Zhou Y, Chen J, Pang Y, Zhang L, Sun X, Yu Z, Jia Y, Wang J, Sun W, Chiu F, Pang L, Wang G.
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [Abstract] [Full Text] [Related]

  • 16. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial.
    Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M.
    Arthritis Res Ther; 2007 Mar; 9(6):R115. PubMed ID: 17986340
    [Abstract] [Full Text] [Related]

  • 17. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.
    Narain S, Berman N, Furie R.
    Curr Opin Rheumatol; 2020 Nov; 32(6):609-616. PubMed ID: 33002950
    [Abstract] [Full Text] [Related]

  • 18. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus.
    Bansal A, Roberts T, Hay EM, Kay R, Pumphrey RS, Wilson PB.
    Clin Exp Immunol; 1992 Sep; 89(3):452-5. PubMed ID: 1387597
    [Abstract] [Full Text] [Related]

  • 19. [New therapeutic perspectives in Sjögren syndrome: leflunomide].
    Scagliusi P, Minenna G, D'Amore M, Scagliusi A.
    Recenti Prog Med; 2005 Apr; 96(4):194. PubMed ID: 15932036
    [No Abstract] [Full Text] [Related]

  • 20. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.
    Remer CF, Weisman MH, Wallace DJ.
    Lupus; 2001 Apr; 10(7):480-3. PubMed ID: 11480845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.